Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in indonesian pulmonary tuberculosis patients

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3614-3619

  Burhan, Erlina ^a   Ruesen, Carolien ^b   Ruslami, Rovina ^c   Ginanjar, Arum ^a   Mangunnegoro, Hadiarto ^a   Ascobat, Purwantyastuti ^a   Donders, Rogier ^b   Van Crevel, Reinout ^b   Aarnoutse, Rob ^b  

^a UNIVERSITY OF INDONESIA   (Indonesia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PADJADJARAN UNIVERSITY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HUMAN; INDONESIA; LUNG LESION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; SPUTUM CULTURE; STEADY STATE; TREATMENT RESPONSE;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDONESIA; ISONIAZID; LUNG; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINAMIDE; RIFAMPIN; RISK FACTORS; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84880278465     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02468-12     Document Type: Article

References (40)

1. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. 1998. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 113:1178-1183.
2. Mehta JB, Shantaveerapa H, Byrd RP, Morton SE, Fountain F, Roy TM. 2001. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 120:1520-1524.
3. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694.
4. Babalik A, Babalik A, Mannix S, Francis D, Menzies D. 2011. Therapeutic drug monitoring in the treatment of active tuberculosis. Can. Respir. J. 18:225-229.
5. Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, Lee CT, Lee JH. 2007. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int. J. Tuberc. Lung Dis. 11:972-978.
6. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, Van der Ven AJ, Danusantoso H, Aarnoutse RE, Van Crevel R. 2006. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin. Infect. Dis. 43:848-854.
7. Narita M, Hisada M, Thimmappa B, Stambaugh J, Ibrahim E, Hollender E, Ashkin D. 2001. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immune deficiency virus status, and other risk factors. Clin. Infect. Dis. 32:515-517.
8. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE. 2009. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 29:503-510.
9. Ruslami R, Nijland HJ, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. 2007. Pharmacokinetics and tolerability of a higher rifampicin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51:2546-2551.
10. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R. 2010. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob. Agents Chemother. 54:1068-1074.
11. McIlleron H, Wash P, Burger A, Norman J, Folb P, Smith P. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177.
12. Seifart HI, Parkin DP, Botha FJH, Donald PR, Van der Walt BJ. 2001. Population screening for isoniazid acetylator phenotype. Pharmacoepidemiol. Drug Safety 10:127-134.
13. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183.
14. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T, Tuberculosis Trials Consortium. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40:1481-1491.
15. Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, Tam CM, Leung EC, Law WS, Leung WM. 2008. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur. J. Clin. Microbiol. Infect. Dis. 27:467-472.
16. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant tuberculosis not due to noncompliance but to betweenpatient pharmacokinetic variability. J. Infect. Dis. 204:1951-1959.
17. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin. Infect. Dis. 55:169-177.
18. World Health Organization (WHO). Accessed 16 July 2012. Tuberculosis profile Indonesia 2012. World Health Organization, Geneva, Switzerland. www.who.int/tb/data.
19. Balows. 1991. Phenotypic DST with proportional method, p 304-340. In Manual of clinical microbiology, 5th ed. ASM Press, Washington, D. C.
20. Aarnoutse R, Sturkenboom M, Robijns K, Harteveld A, Greijdanus B, Uges D, Touw D, Alffenaar J. 2012. An international interlaboratory quality control (QC) program for bio-analysis of tuberculosis drugs, abstr. O-20. 5th International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, C. A.
21. Hutchings A, Routledge PA. 1986. A simple method for determining acetylator phenotype using isoniazid. Br. J. Clin. Pharmacol. 22:343-345.
22. Perrin FMR, Lipman MCI, McHugh TD, Gillespie SH. 2007. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect. Dis. 7:481-490.
23. Holdiness MR. 1984. Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 9:511-544.
24. Peloquin CA. 1991. Antituberculosis drugs: pharmacokinetics, p 59-88. In Heifets L (ed), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Inc, Boca Raton, F. L.
25. Aarnoutse R, Donald PR, van Helden PD. 2011. Antituberculosis chemotherapy. Prog. Respir. Res. Basel Karger 40:176-190.
26. Meyer UA, Zanger UM. 1997. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37:269-296.
27. McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Conolly C, Rida W, Pym A, Smith PJ, Onyebujoh PC. 2012. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob. Agents Chemother. 56:3232-3238.
28. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Maya Purwa A, Ahmad Y, Ottenhoff T, Nelwan RHH, Parwati I, Van der Meer JWM, Van Crevel R. 2007. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin. Infect. Dis. 45:428-435.
29. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. 2011. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob. Agents Chemother. 55:1527-1532.
30. Gumbo T, Dona CS, Meek C, Leff R. 2009. Pharmacokineticspharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53:3197-3204.
31. Nuermberger EL, Grosset J. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microb. Infect. Dis. 23:243-255.
32. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
33. Diacon AH, Patienta RF, Venter A, Van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. 2007. Early bactericidal activity of highdose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51:2994-2996.
34. Mitchison DA 2000. Role of individual drugs in the treatment of tuberculosis. Int. J. Tuberc. Lung Dis. 4:796-806.
35. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Makesh BN, Yayashree R, Nandi V, Bharath S, Kantharaj E, Balasubramanian V. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957.
36. Firsov AA, Dombrovskii VS, Kadenatsi IB, Gagaeva EV, Strachunskii LS. 1996. Correlation between pharmacokinetic parameters of rifampicin and its biologically active metabolite as related to estimation of the relative bioavailability of the antibiotic. Antibiot. Chemother. 41:36-43.
37. Endrenyi L, Fritsch S, Yan W. 1991. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int. J. Clin. Pharmacol. Ther. Toxicol. 29:394-399.
38. Aarnoutse RE, Mooren FW, Nijland H, Apriyani L, Wieringa F, Van Crevel R, Ruslami R. 2011. Evaluation of protein-unbound, active concentrations of rifampicin in Indonesian tuberculosis patients, abstr. O01. Abstr. 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs.
39. Phillips PJ, Davies GR, Mitchison DA. 2010. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis. 10:69-70.
40. Phillips PJ, Fielding K. 2008. Surrogate markers for poor outcome to treatment for tuberculosis: results from extensive multi-trial analysis. Int. J. Tuberc. Lung Dis. 12:S146-S147.